A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

Hartmut Döhner; Carsten Müller‐Tidow; Michael Lübbert; Walter Fiedler; Alwin Krämer; Jörg Westermann; Gesine Bug; Richard F. Schlenk; Utz Krug; Rainer‐Georg Goeldner; James Hilbert; Tillmann Taube; Oliver G. Ottmann

doi:10.1111/bjh.15563

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

British Journal of Haematology ◽

10.1111/bjh.15563 ◽

2018 ◽

Vol 185 (3) ◽

pp. 583-587

Author(s):

Hartmut Döhner ◽

Carsten Müller‐Tidow ◽

Michael Lübbert ◽

Walter Fiedler ◽

Alwin Krämer ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Aurora B ◽

Aurora B Kinase ◽

Acute Myeloid

Download Full-text

497 Combination therapy with an Aurora B kinase inhibitor AZD1152 and AraC, shows enhanced tumouricidal activity in a preclinical model of acute myeloid leukaemia (AML)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72204-7 ◽

2010 ◽

Vol 8 (7) ◽

pp. 159

Author(s):

R.W. Wilkinson ◽

R. Odedra ◽

S.V. Holt ◽

J.R. Foster ◽

E. Anderson

Keyword(s):

Combination Therapy ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Preclinical Model ◽

Aurora B ◽

Aurora B Kinase ◽

Acute Myeloid

Download Full-text

A phase I trial of allogeneic tumour-activated natural killer lymphocytes for the treatment of selected patients with acute myeloid leukaemia.

http://isrctn.com/ ◽

10.1186/isrctn11950134 ◽

2014 ◽

Author(s):

Mark Lowdell

Keyword(s):

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Natural Killer ◽

Phase I Trial ◽

Natural Killer Lymphocytes ◽

Acute Myeloid

Download Full-text

A Phase I trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation

http://isrctn.org/> ◽

10.1186/isrctn98163167 ◽

2014 ◽

Author(s):

Kathryn Wheeler

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Salvage Therapy ◽

Phase I Trial ◽

Acute Myeloid

Download Full-text

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1939-2 ◽

2012 ◽

Vol 70 (3) ◽

pp. 461-469 ◽

Cited By ~ 37

Author(s):

Mike Dennis ◽

Michelle Davies ◽

Stuart Oliver ◽

Roy D’Souza ◽

Laura Pike ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Study ◽

Kinase Inhibitor ◽

Aurora B ◽

Aurora B Kinase ◽

Acute Myeloid

Download Full-text

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

Clinical & Translational Immunology ◽

10.1002/cti2.1117 ◽

2020 ◽

Vol 9 (3) ◽

Author(s):

Felix S Lichtenegger ◽

Frauke M Schnorfeil ◽

Maurine Rothe ◽

Katrin Deiser ◽

Torben Altmann ◽

...

Keyword(s):

Dendritic Cells ◽

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Phase I Trial ◽

Toll Like Receptor ◽

Acute Myeloid

Download Full-text

P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA

BMC Cancer ◽

10.1186/1471-2407-11-254 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 12

Author(s):

Martin Grundy ◽

Claire Seedhouse ◽

Nigel H Russell ◽

Monica Pallis

Keyword(s):

Breast Cancer ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Breast Cancer Resistance Protein ◽

Kinase Inhibitor ◽

Aurora B ◽

Cancer Resistance ◽

P Glycoprotein ◽

Resistance Protein ◽

Acute Myeloid

Download Full-text

A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia

British Journal of Haematology ◽

10.1111/bjh.12518 ◽

2013 ◽

pp. n/a-n/a ◽

Cited By ~ 2

Author(s):

Carsten Müller-Tidow ◽

Gesine Bug ◽

Michael Lübbert ◽

Alwin Krämer ◽

Jürgen Krauter ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Maximum Tolerated Dose ◽

Open Label ◽

Open Label Phase ◽

Bi 2536 ◽

Acute Myeloid

Download Full-text

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

Leukemia Research ◽

10.1016/j.leukres.2011.04.008 ◽

2011 ◽

Vol 35 (10) ◽

pp. 1384-1389 ◽

Cited By ~ 35

Author(s):

Kosuke Tsuboi ◽

Toshiya Yokozawa ◽

Toru Sakura ◽

Takashi Watanabe ◽

Shin Fujisawa ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Phase I ◽

Myeloid Leukemia ◽

Phase I Study ◽

Kinase Inhibitor ◽

Japanese Patients ◽

Aurora B ◽

Aurora B Kinase ◽

Acute Myeloid

Download Full-text

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

British Journal of Haematology ◽

10.1111/bjh.15204 ◽

2018 ◽

Vol 184 (6) ◽

pp. 1018-1021 ◽

Cited By ~ 9

Author(s):

Oliver G. Ottmann ◽

Carsten Müller-Tidow ◽

Alwin Krämer ◽

Richard F. Schlenk ◽

Michael Lübbert ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Phase I ◽

Myeloid Leukaemia ◽

Dose Escalation ◽

Acute Myeloid

Download Full-text

Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia

British Journal of Haematology ◽

10.1111/bjh.16665 ◽

2020 ◽

Vol 191 (2) ◽

pp. 231-242

Author(s):

Joanna Zabkiewicz ◽

Michelle Lazenby ◽

Gareth Edwards ◽

Ceri A. Bygrave ◽

Nader Omidvar ◽

...

Keyword(s):

Cell Adhesion ◽

Protein Kinase ◽

Acute Myeloid Leukaemia ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Residual Disease ◽

Mitogen Activated Protein Kinase ◽

Mitogen Activated Protein ◽

Acute Myeloid

Download Full-text